Reviva Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 15
- Market Cap
- -
- Website
- http://www.revivapharma.com
- Introduction
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.
Reviva to Present Long-Term Phase 3 Data for Brilaroxazine in Schizophrenia at SIRS Congress
Reviva Pharmaceuticals will present topline data from the 52-week open-label extension portion of their Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia at the 2025 SIRS Congress in Chicago.
Reviva Pharmaceuticals' Brilaroxazine Receives Buy Rating Following Positive Phase 3 Schizophrenia Data
Roth MKM initiated coverage of Reviva Pharmaceuticals with a Buy rating, citing positive Phase 3 data for brilaroxazine in treating schizophrenia.
Xanomeline/Trospium Chloride Shows Cognitive Improvement in Schizophrenia; MindMed's LSD Trial Begins
Xanomeline/trospium chloride (Cobenfy) improved cognition in schizophrenia patients with baseline cognitive impairment, according to an exploratory analysis of two phase III trials.
Reviva's Brilaroxazine Shows Sustained Efficacy and Safety in Schizophrenia Patients Over One Year
Reviva Pharmaceuticals' brilaroxazine demonstrated sustained efficacy and a favorable safety profile over one year in patients with schizophrenia in the Phase 3 RECOVER study's open-label extension (OLE).
AbbVie's Emraclidine Fails, Bolstering BMS's Lead in Schizophrenia Treatment
AbbVie's emraclidine failed to demonstrate statistically significant improvement in schizophrenia symptoms in Phase II trials, a setback for the muscarinic pathway approach.
Reviva Presents Positive Speech Latency Data for Brilaroxazine in Schizophrenia from Phase 3 RECOVER Trial
Reviva Pharmaceuticals announced positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial.
Reviva Presents Positive Brilaroxazine Data on Speech Latency in Schizophrenia from Phase 3 RECOVER Trial
Reviva Pharmaceuticals announced positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial.
Reviva Pharma's Brilaroxazine Shows Positive Speech Latency Data in Phase 3 Schizophrenia Trial
Reviva Pharmaceuticals will present positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial at the CNS Summit 2024.
Bipolar Disorder Pipeline Shows Promise with 22+ Emerging Therapies
Over 22 pharmaceutical and biotech companies are actively developing more than 22 pipeline drugs for bipolar disorder, addressing a significant unmet need.
Schizophrenia Clinical Trial Pipeline Boasts 60+ Drugs Under Development
The schizophrenia treatment landscape is expanding with over 60 drugs in active development, driven by increased R&D and innovative therapies.